Intuitive Surgical (NASDAQ:ISRG) Stock Price Up 1.3% – What’s Next?

Intuitive Surgical, Inc. (NASDAQ:ISRG) shares were up 1.3% during trading on Thursday . The stock traded as high as $584.08 and last traded at $580.02. Approximately 400,239 shares were traded during trading, a decline of 79% from the average daily volume of 1,931,788 shares. The stock had previously closed at $572.71.

Analysts Set New Price Targets

Several research firms recently commented on ISRG. Raymond James increased their price objective on Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. UBS Group raised their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research note on Monday. Royal Bank of Canada upped their price objective on shares of Intuitive Surgical from $611.00 to $641.00 in a research note on Monday. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. Finally, Morgan Stanley upgraded Intuitive Surgical from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $522.00 to $650.00 in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Price Performance

The firm has a market capitalization of $206.65 billion, a price-to-earnings ratio of 93.28, a PEG ratio of 5.19 and a beta of 1.39. The stock has a 50 day moving average price of $549.32 and a two-hundred day moving average price of $507.50.

Insiders Place Their Bets

In other news, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jamie Samath sold 94 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total value of $53,684.34. Following the transaction, the chief financial officer now directly owns 2,630 shares of the company’s stock, valued at $1,502,019.30. The trade was a 3.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,843 shares of company stock worth $15,357,560 over the last three months. Company insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Several hedge funds have recently added to or reduced their stakes in the company. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at $26,000. Godsey & Gibb Inc. lifted its holdings in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the last quarter. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical during the 3rd quarter worth about $33,000. Decker Retirement Planning Inc. acquired a new position in shares of Intuitive Surgical during the 4th quarter worth about $36,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Intuitive Surgical in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.